Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jaypirca
Pharma
Lilly’s BTK drug Jaypirca enters first-line CLL
Despite a positive first-line readout, Lilly’s Jake Van Naarden has maintained that the primary use of Jaypirca “remains in second line.”
Angus Liu
Oct 2, 2026 4:15pm
Europe's CHMP reverses endorsement of Amgen's Tavneos
Jun 26, 2026 11:07am
Lilly oncology chief ‘blown away’ by new Jaypirca CLL data
Jun 15, 2026 8:25am
BeOne's Venclexta challenger Beqalzi nets FDA approval
May 13, 2026 4:45pm
Why Lilly is betting on 2nd-line CLL despite 1st-line wins
Dec 9, 2025 7:30am
Lilly's BTK inhibitor Jaypirca wins lymphoma label expansion
Dec 3, 2025 8:25am
